Do you gain weight back after stopping Wegovy — and does it happen to everyone?

Step 1: understand what the trial data actually show

The clearest evidence comes from the STEP 1 extension study. Participants who completed 68 weeks on semaglutide 2.4mg and then stopped treatment were followed for a further year. On average, they regained roughly two-thirds of the weight they had lost, returning to within about a third of their original body weight. This figure is cited in the STEP 1 trial, published in the New England Journal of Medicine, alongside NHS guidance, and it forms the basis of most clinical conversations about stopping.

Two things matter here. First, "two-thirds" is a mean, not a law, some people regained very little; others regained more. Second, the study stopped treatment abruptly; a planned, gradual withdrawal supported by a prescriber may produce a different pattern, though the evidence for tapering is not yet definitive. If you are specifically asking whether you gain weight back after stopping semaglutide, the honest answer is that for the majority, some regain is the realistic expectation.

If you want to explore whether Wegovy works for everyone in the first place, that context is worth reading alongside this one.

Step 2: understand the biology behind the regain

Semaglutide reduces appetite partly by acting on GLP-1 receptors in areas of the brain involved in hunger and satiety. It also slows gastric emptying, which extends the feeling of fullness after meals. Both effects reverse when the medicine clears the body, which takes several weeks given semaglutide's roughly one-week half-life.

As appetite signals normalise, many people notice hunger returning more sharply than expected. This is not a failure of willpower. The body has its own defended weight setpoint (a biological target it tries to return to) and without the pharmacological brake, that pull reasserts itself. The NHS medicines information on semaglutide notes that the medicine is intended for long-term use alongside lifestyle changes, precisely because the condition it treats (obesity) is chronic. Stopping it removes one of the main tools holding appetite in check.

The speed of regain tends to track how quickly appetite returns. Weeks two to eight after the last dose are often when hunger feels most pronounced, which is also when food choices matter most. Planning for that window before stopping (rather than during it) is something our clinical team regularly discusses with patients considering a break.

Step 3: what genuinely reduces the risk of regaining everything

No lifestyle intervention fully offsets the biological effects of stopping semaglutide, but the gap between "most regain" and "all regain" is real and worth understanding. People who built consistent habits during treatment tend to fare better: adequate protein at each meal reduces the acute hunger signal; strength training preserves muscle mass (which supports metabolic rate); and structured eating patterns make it easier to hold ground when appetite surges.

Timing also plays a role in how well preparation works. Stopping abruptly (around a holiday, for instance, or because a repeat order felt like too much admin on a busy Monday) tends to go less well than a planned transition. Building the conversation with your prescriber into the run-up to a planned stop gives time to adjust diet targets and activity levels before hunger climbs back.

There is also growing clinical interest in whether a lower maintenance dose, rather than a full stop, can preserve some benefit. That is an active area of prescriber practice, and the right approach depends on individual health factors. You can read more about the broader picture of weight gain when stopping Wegovy and how it is typically managed.

Step 4: what this means if you are considering treatment or a restart

Knowing that weight commonly returns after stopping does not mean treatment is pointless. The clinical rationale for Wegovy is long-term weight management, with the expectation that many people will need to continue for years, not months. NICE's recommendations for semaglutide (TA875) acknowledge this chronic-disease framing, and the NHS explicitly treats obesity as a long-term condition rather than something a short course of treatment cures.

For anyone weighing up the cost and commitment involved, an overview of weight-management options may help clarify the broader picture. And if cost is part of your thinking, understanding what's included in a private Wegovy prescription is a practical starting point, legitimate private treatment includes clinical assessment, not just a pen in the post.

If you stopped treatment and regained weight, our page on whether you put weight back on after stopping Wegovy covers what restarting involves and what to expect clinically. Restarting is medically possible for most people, subject to clinical review. The prescriber will want to understand why you stopped, your current health status, and what support is in place this time. Every prescription at nume goes through a fresh clinical review before it is issued. If you'd like to discuss your situation with a prescriber, starting a free consultation is straightforward and confidential.